#Portugal #Expert Systems #Mondego Bio #PTPN2 inhibitors #Cantanhede

Launch of Mondego Bio: A Groundbreaking Step in Immuno-Oncology

On September 29, 2025, Expert Systems Inc. celebrated the inception of a new venture, Mondego Bio, which is set to make waves in the field of cancer treatment. This promising immuno-oncology company has secured Series A funding, a critical step in its mission to address the immune resistance faced by solid tumors in oncology.

A Strategic Initiative to Tackle Immuno-Resistance

Headquartered at Biocant Park in Cantanhede, Portugal, Mondego Bio has positioned itself strategically to tackle one of the most pressing challenges in cancer therapy today: overcoming immune resistance in solid tumors. This initiative has garnered the backing of notable investors including Biovance Capital, Torrey Pines Investment, and OrbiMed, emphasizing the robust financial foundation for its ambitious goals.

Pioneering PTPN2 Inhibitors

As a frontrunner in the field, Mondego Bio is focused on developing a portfolio of first- and best-in-class PTPN2 inhibitors. These innovative drug candidates are designed to enhance cancer immunotherapy by combining oral bioavailability, high selectivity, and favorable safety profiles. The potential of these inhibitors lies in their ability to be integrated into combination immuno-oncology regimens, thus elevating their therapeutic effectiveness.

Dr. Tudor Oprea, CEO of Expert Systems Inc., remarked on the significance of this venture: "Solid tumors remain one of the greatest unmet needs in medicine. Our integration of predictive ADMET and PK/PD modeling with new-approach methodologies (NAMs) gives Mondego Bio a decisive edge, allowing us to identify high-potential PTPN2 inhibitors and fast-track them into development."

Accelerating Pathways to Clinical Readiness

The efficiency of the drug development process has been dramatically improved through Expert Systems' AI/ML-driven molecular design and predictive pharmacology platform. This cutting-edge technology accelerates the timeline from concept to clinical readiness, maximizing the potential for successful outcomes in the fight against cancer.

With these first- and best-in-class PTPN2 inhibitors, Mondego Bio is set to transform the landscape of cancer immunotherapy, bringing hope to millions facing solid tumor diagnoses.

The Future Ahead

Expert Systems will continue its strategic partnership with Mondego Bio, providing essential scientific and technological support as the company progresses towards its first-in-human studies. This collaboration showcases the unique capabilities of Expert Systems in creating and scaling high-value biotech ventures, effectively mitigating risk for investors and partners embroiled in early-stage innovation.

By bridging the gap between lab discovery to clinical application, Mondego Bio is positioned to deliver compelling biotech opportunities with clear exit pathways, ultimately aiming to enhance patient outcomes. This innovative stride marks an exciting chapter in the world of pharmaceuticals, one where the battle against cancer is approached with renewed vigor and a focus on cutting-edge technology and research.

For more information about this groundbreaking launch and its implications for the future of cancer treatment, please visit Expert Systems' official page.